Literature DB >> 417019

Inhibition of C5 convertase by epsilon amino caproic acid (EACA): a limiting factor in the generation of C5a anaphylatoxin.

E H Vallota.   

Abstract

The effect of EACA on spontaneous C5 consumption and on the mechanisms of C5 activation through the alternative pathway of complement were analyzed. In contrast to the effect upon C3, ADDITION OF 1 M EACA to normal human serum (NHS) did not enhance spontaneous consumption of C5, but augmented its haemolytic efficiency. In the presence of 1 M EACA, activation of serum with zymosan (Z), resulted in inhibition of the formation of C5 convertase, and thus of C5 cleavage and C5a anaphylatoxin release. The generation of a C5 convertase on activated zymosan (Z) was inhibited when Z was formed at 17 degrees with NHS containing 1 M EACA. In contrast, if Z was formed in the absence of EACA the C5 convertase could be regenerated with fresh serum containing 1M EACA. Nearly maximal C5 consumption was obtained if 5 mM EGTA and 10 mM MgCl2 were added to the mixture. These conditions are considered optimal for generation and maximum recovery of fully active anaphylatoxin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 417019      PMCID: PMC1457616     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

3.  Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

4.  Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.

Authors:  T F Lint; C L Behrends; P J Baker; H Gewurz
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

5.  Inactivator of the third component of complement as an inhibitor in the properdin pathway.

Authors:  C A Alper; F S Rosen; P J Lachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

6.  Purification and partial characterization of human and porcine C3a anaphylatoxin.

Authors:  T E Hugli; E H Vallota; H J Müller-Eberhard
Journal:  J Biol Chem       Date:  1975-02-25       Impact factor: 5.157

7.  Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

8.  Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator.

Authors:  E H Vallota; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1973-05-01       Impact factor: 14.307

9.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  2 in total

1.  Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.

Authors:  R Huey; C M Bloor; M S Kawahara; T E Hugli
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

2.  Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency.

Authors:  L Cui; D F Carney; T E Hugli
Journal:  Protein Sci       Date:  1994-08       Impact factor: 6.725

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.